Wednesday, 24 March 2021
  0 Replies
  6.6K Visits


This working copy of the document Considerations for optimizing deployment of ChAdOx1-S [recombinant] vaccines in a time-limited constrained supply situation (AstraZeneca/AZD1222-Vaxzevria, AstraZeneca/SK Bioscience and SII/Covishield vaccines) provides an overview of the scientific basis and key programmatic considerations to guide national decision-making for countries on optimizing the deployment of AstraZeneca/AZD1222 and SII/Covishield vaccines under circumstances where vaccine supply is constrained, and future quantities and delivery dates cannot be reliably predicted.

Further details on the available evidence and key studies are available at the SAGE website, while resources for implementation and training are available at the COVID-19 vaccine introduction toolkit webpage.

There are no replies made for this post yet.